Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
— STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors.
— Study to evaluate tertiary lymphoid structure (TLS) and high endothelial venule (HEV) formation in the tumor as well as clinical responses, as monotherapy and in combination with PD-1 inhibitor Keytruda® (pembrolizumab).
Cambridge, UK, May 19, 2026 – Mestag Therapeutics, a clinical-stage biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, today announced the dosing of the first patient in a Phase 1 clinical trial evaluating MST-0312 in patients with selected advanced solid tumors. The first in human trial, named the STARLYS trial, is an adaptive, modular multi-part, multi-arm open-label study designed to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and anti-tumor activity of MST-0312 alone and in combination with pembrolizumab.
